Watch CAMP. Know when insiders buy.
One email the day a filing lands. Free.
CAMP
Camp4 Therapeutics Corp
4.41
−0.08 −1.78%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
60
WATCH · insiders 30, shorts 90
Insiders, 90 days
−$2.5M
net selling · 1 buy, 4 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $276.7MP/E —DIV YIELD —FCF YIELD -10.38%REV TTM $4.2M +40.2%NET INCOME −$107.2MNET CASH —52W 1.65 – 7.13SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $1.8M | +18.8% | — | −$13.4M | −$33.5M | — | -0.58 | −$12.7M | $129K | −$12.8M | Aug 13 |
| Q1 2026 · Mar 31 | $1.3M | +50.8% | — | −$13.1M | −$18.3M | — | -0.32 | −$11M | $0 | −$11M | Aug 13 |
| Q4 2025 · Dec 31derived | $348K | −46.6% | — | −$12.8M | −$40.3M | — | -0.87 | $6.3M | $0 | $6.3M | Mar 5 |
| Q3 2025 · Sep 30 | $795K | — | — | −$13.7M | −$15.1M | — | -0.55 | −$11.2M | $0 | −$11.2M | Nov 6 |
| Q2 2025 · Jun 30 | $1.5M | — | — | −$13M | −$12.6M | — | -0.62 | −$10.3M | $0 | −$10.3M | Aug 13 |
| Q1 2025 · Mar 31 | $858K | — | — | −$13.1M | −$12.4M | — | -0.62 | −$14.3M | $279K | −$14.6M | Aug 13 |
| Q4 2024 · Dec 31derived | $652K | — | — | −$14M | −$13.3M | — | 65.46 | −$11.3M | $263K | −$11.6M | Mar 5 |
| Q3 2024 · Sep 30 | $0 | −100.0% | — | −$13.5M | −$13.5M | — | -24.19 | −$9.7M | $0 | −$9.7M | Nov 6 |
| Q2 2024 · Jun 30 | $0 | — | — | −$12.7M | −$12.6M | — | -26.00 | −$13.4M | $163K | −$13.6M | Nov 6 |
| Q1 2024 · Mar 31 | $0 | — | — | −$12.9M | −$12.5M | — | -26.57 | −$11.1M | $15K | −$11.2M | Nov 6 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$13.5M | −$13M | — | -30.18 | −$11.8M | $243K | −$12M | Mar 27 |
| Q3 2023 · Sep 30 | $350K | — | — | −$12.3M | −$11.7M | — | -29.21 | — | — | — | Nov 21 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $3.5M | — | −$52.6M | −$80.4M | -2298.5% | -2.65 | −$29.6M | $279K | −$29.8M | — | — |
| FY2024 · to Dec 31 | $652K | — | −$53.1M | −$51.8M | -7943.4% | -11.04 | −$45.6M | $441K | −$46M | — | — |
| FY2023 · to Dec 31 | $350K | — | −$51.9M | −$49.3M | -14083.1% | -124.80 | −$44.2M | $678K | −$44.8M | — | — |
Every number comes from Camp4 Therapeutics Corp's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.